Search International and National Patent Collections

1. (WO2018218875) OCTS TECHNOLOGY-BASED PROSTATE CANCER CAR-T THERAPEUTIC VECTOR, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF

Pub. No.:    WO/2018/218875    International Application No.:    PCT/CN2017/110664
Publication Date: Fri Dec 07 00:59:59 CET 2018 International Filing Date: Tue Nov 14 00:59:59 CET 2017
IPC: C12N 15/867
C12N 15/62
C12N 5/10
A61K 35/17
A61P 35/00
Applicants: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
上海优卡迪生物医药科技有限公司
Inventors: QI, Wei
祁伟
YU, Lei
俞磊
KANG, Liqing
康立清
LIN, Gaowu
林高武
YU, Zhou
余宙
Title: OCTS TECHNOLOGY-BASED PROSTATE CANCER CAR-T THERAPEUTIC VECTOR, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF
Abstract:
Provided is a prostate cancer CAR-T therapeutic vector targeting both PSMA and PDL1, comprising a lentiviral backbone plasmid, a human EF1α promoter, a double targeting chimeric receptor domain, and a PDL1 single-chain antibody. The double targeting chimeric receptor domain comprises a CD8 leader chimeric receptor signal peptide, a PSMA single-chain antibody light chain variable region, a PSMA single-chain antibody heavy chain variable region, a PDL1 single-chain antibody light chain variable region, a PDL1 single-chain antibody heavy chain variable region, an inner-antibody hinge, an inter-single-chain antibody hinge, a CD8 chimeric receptor hinge, a CD8 chimeric receptor transmembrane region, a TCR chimeric receptor T cell activation domain, and a chimeric receptor costimulatory factor region. Also provided are a method for constructing said vector and use thereof in the preparation of a medicament for treating prostate cancer.